BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26221190)

  • 21. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
    Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R
    BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.
    Quek C; Rawson RV; Ferguson PM; Shang P; Silva I; Saw RPM; Shannon K; Thompson JF; Hayward NK; Long GV; Mann GJ; Scolyer RA; Wilmott JS
    Oncotarget; 2019 Jan; 10(9):930-941. PubMed ID: 30847022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.
    Kunz M; Hölzel M
    Cancer Metastasis Rev; 2017 Mar; 36(1):53-75. PubMed ID: 28210865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.
    Herlihy N; Dogrusöz M; van Essen TH; Harbour JW; van der Velden PA; van Eggermond MC; Haasnoot GW; van den Elsen PJ; Jager MJ
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(3):1447-58. PubMed ID: 25593028
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome-wide DNA methylation profile of leukocytes from melanoma patients with and without CDKN2A mutations.
    de Araújo É; Marchi FA; Rodrigues TC; Vieira HC; Kuasne H; Achatz MI; Moredo LF; de Sá BC; Duprat JP; Brentani HP; Rosenberg C; Carraro DM; Krepischi AC
    Exp Mol Pathol; 2014 Dec; 97(3):425-32. PubMed ID: 25236571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNAs mediated targeting on the Yin-yang dynamics of DNA methylation in disease and development.
    Tu J; Liao J; Luk AC; Tang NL; Chan WY; Lee TL
    Int J Biochem Cell Biol; 2015 Oct; 67():115-20. PubMed ID: 25979370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Genetic Evolution of Melanoma from Precursor Lesions.
    Shain AH; Yeh I; Kovalyshyn I; Sriharan A; Talevich E; Gagnon A; Dummer R; North J; Pincus L; Ruben B; Rickaby W; D'Arrigo C; Robson A; Bastian BC
    N Engl J Med; 2015 Nov; 373(20):1926-36. PubMed ID: 26559571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent inactivating mutations of ARID2 in non-small cell lung carcinoma.
    Manceau G; Letouzé E; Guichard C; Didelot A; Cazes A; Corté H; Fabre E; Pallier K; Imbeaud S; Le Pimpec-Barthes F; Zucman-Rossi J; Laurent-Puig P; Blons H
    Int J Cancer; 2013 May; 132(9):2217-21. PubMed ID: 23047306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic events in malignant melanoma.
    Rothhammer T; Bosserhoff AK
    Pigment Cell Res; 2007 Apr; 20(2):92-111. PubMed ID: 17371436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma.
    Guan J; Gupta R; Filipp FV
    Sci Rep; 2015 Jan; 5():7857. PubMed ID: 25600636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia.
    Mar BG; Bullinger LB; McLean KM; Grauman PV; Harris MH; Stevenson K; Neuberg DS; Sinha AU; Sallan SE; Silverman LB; Kung AL; Lo Nigro L; Ebert BL; Armstrong SA
    Nat Commun; 2014 Mar; 5():3469. PubMed ID: 24662245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonsynonymous somatic mitochondrial mutations occur in the majority of cutaneous melanomas.
    Mithani SK; Smith IM; Topalian SL; Califano JA
    Melanoma Res; 2008 Jun; 18(3):214-9. PubMed ID: 18477896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.